Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

n the United States there are approximately 1,500 new cases each year.

About Ibrutinib
Ibrutinib is an investigational drug designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness and safety of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 27 trials are currently registered on clinicaltrials.gov.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... According to a new market research report ... by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... Million by 2020 from $452.36 Million in 2015, growing ... 71 market data Tables and 90 Figures spread through ...
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Patient Safety Technologies, Inc. (the "Company", OTCQB: PSTX) ... full fiscal year end 2010. Financial ... hospitals using the Company,s SurgiCount Safety-Sponge® System more than ... proportional to future revenues, the number of hospitals using ...
... Reportlinker.com announces that a new market research ... Sleep Disorders Market to 2017 ... Pipeline Will Negatively Impact the Market ... Sleep Disorders Market to 2017 - ...
Cached Medicine Technology:Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 2Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 3Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 4Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 5Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 6Patient Safety Technologies Reports Fiscal 2010 Fourth Quarter and Full Year Results 7Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 2Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 3Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 4Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 5Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 6Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 7Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 8Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 9Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 10Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 11Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 12Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 13Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 14Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 15Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market 16
(Date:5/24/2015)... (PRWEB) May 24, 2015 Scientists with ... paper on air quality compliance issues that may have ... workers. Surviving Mesothelioma has just posted an article on ... , The group found airborne asbestos levels well ... collected between 1984 and 2011. , “Asbestos compliance sampling ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Krihak as its head of programmatic strategy and ... expertise and leadership position in the data driven ... , Krihak is an experienced, award-winning agency and ... sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... Dr. David Benvenuti, an experienced plastic surgeon ... new article to his website that takes an ... explained in the fascinating blog, he has recently had ... , Known as “gauging,” the technique involves placing larger and ... said will eventually stretch the holes out to incredible sizes. ...
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood company in ... reclaimed wood, introducing their latest reclaimed wood products at ... offerings, Vat 35, Reclaimed Teak , and Prairie ... largest design event. , “Designers, architects, builders, and homeowners ... see and feel the variety of wood surfaces in ...
Breaking Medicine News(10 mins):Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3
... Intimate Partner Violence May Have Benefits, Few Harms ... range of abusive behaviors perpetrated by someone who is ... may include physical violence, sexual violence, rape, and psychological ... on the victim. While victims and perpetrators can be ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... cold will try almost anything to relieve their symptoms, but ... Canadian analysis has revealed that zinc tablets may help patients ... "Although it is possible that oral zinc preparations impact symptoms ...
... By Randy Dotinga HealthDay Reporter , MONDAY, ... yourself? An opinion, perhaps, or a status update? Nobody may ... make yourself feel good simply by sharing. Participants who ... of the brain that are linked to value and motivation, ...
... By Randy Dotinga HealthDay Reporter , MONDAY, May 7 ... of the TV have poorer diets overall, a new study of ... TV watching has anything to do with what kids eat, and ... important than time spent with "American Idol" or "SpongeBob SquarePants." ...
... coli bacteria early in life have a higher number of ... carried out at the Sahlgrenska Academy at the University of Gothenburg, ... our bodies by a factor of ten and are extremely important ... system. The normal bacterial flora in the gut is established at ...
... tool in the fight against breast cancer, but it has ... give in false positive and negative results; it also exposes ... accepted as safe still carry some risk. In ... device, researchers from Netherlands, University of Twente and Medisch Spectrum ...
Cached Medicine News:Health News:Annals of Internal Medicine tip sheet for May 8, 2012, online issue 2Health News:Zinc Pills May Shorten Colds, Analysis Suggests 2Health News:People Love Talking About Themselves, Brain Scans Show 2Health News:Lots of TV May Harm Kids' Diet 2Health News:Lots of TV May Harm Kids' Diet 3Health News:Gut flora affects maturation of B cells in infants 2Health News:Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: